CDP-Choline (Citicoline)

Overview

CDP-choline (citicoline) is a non-peptide cytidine nucleotide-choline conjugate that serves as an intermediate in phosphatidylcholine biosynthesis. It is approved as a prescription drug for stroke and cognitive disorders in Japan and parts of Europe but sold only as a dietary supplement ingredient in the United States, where it is not FDA-approved as a drug. Human evidence is mixed and indication-dependent: small trials report modest memory improvements in healthy/older adults, but the largest phase 3 RCT (COBRIT, n=1,213 traumatic brain injury patients) found no benefit over placebo.

Mechanism of Action

Citicoline is hydrolyzed in the gut wall and liver into cytidine and choline; both cross the blood-brain barrier separately and are re-synthesized into CDP-choline within cells, which then donates the phosphocholine moiety for phosphatidylcholine (membrane phospholipid) synthesis. Downstream effects reported in preclinical and review literature include acceleration of phospholipid resynthesis in injured membranes, preservation of membrane lipids, restoration of Na⁺/K⁺-ATPase and mitochondrial ATPase activity, increased glutathione synthesis, and increases in CNS acetylcholine, norepinephrine, and dopamine. A SIRT1-dependent neuroprotective mechanism has been reported in a mouse stroke model.

Research Summary

Human evidence is mixed and indication-dependent. Small-to-moderate placebo-controlled RCTs in healthy/older adults and age-associated memory impairment report modest verbal/episodic memory improvements at ~500–1,000 mg/day over weeks to months. However, the largest trial to date—COBRIT, a phase 3 double-blind placebo-controlled RCT in 1,213 traumatic brain injury patients—found no benefit over placebo on functional or cognitive outcomes (GOS-E favorable outcome 35.4% citicoline vs 35.6% placebo; global OR 0.98, 95% CI 0.83–1.15). Evidence for Alzheimer's disease and MCI is described in reviews as insufficient and inconsistent. In preclinical models, aged rats with hippocampal damage showed reduced long-term memory impairment with dietary CDP-choline supplementation, and mice subjected to ischemic stroke showed SIRT1-dependent reduction in cerebral infarct volume.

Reported Side Effects

• Mild digestive intolerance (~5% pooled adverse event rate across 2,817 patients)
• Occasional self-limiting headache
• Tingling or numbness (rare)
• No clinically significant ECG or EEG abnormalities recorded in reviewed studies
• Null efficacy in largest TBI trial (COBRIT, n=1,213) — not a safety signal but relevant to efficacy expectations

Compare CDP-Choline (Citicoline) with Others

Research References

• Citicoline, CID 13804 (PubChem Compound Summary).
• Citicoline: pharmacological and clinical review, 2006 update. 2006. PMID 17171187.
• The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives. 2015.
• Citicoline for Supporting Memory in Aging Humans.

Frequently asked questions

How does CDP-Choline (Citicoline) work?

Citicoline is hydrolyzed in the gut wall and liver into cytidine and choline; both cross the blood-brain barrier separately and are re-synthesized into CDP-choline within cells, which then donates the phosphocholine moiety for phosphatidylcholine (membrane phospholipid) synthesis. Downstream effects reported in preclinical and review literature include acceleration of phospholipid resynthesis in injured membranes, preservation of membrane lipids, restoration of Na⁺/K⁺-ATPase and mitochondrial ATPase activity, increased glutathione synthesis, and increases in CNS acetylcholine, norepinephrine, and dopamine. A SIRT1-dependent neuroprotective mechanism has been reported in a mouse stroke model.

What does the research say about CDP-Choline (Citicoline)?

Human evidence is mixed and indication-dependent. Small-to-moderate placebo-controlled RCTs in healthy/older adults and age-associated memory impairment report modest verbal/episodic memory improvements at ~500–1,000 mg/day over weeks to months. However, the largest trial to date—COBRIT, a phase 3 double-blind placebo-controlled RCT in 1,213 traumatic brain injury patients—found no benefit over placebo on functional or cognitive outcomes (GOS-E favorable outcome 35.4% citicoline vs 35.6% placebo; global OR 0.98, 95% CI 0.83–1.15). Evidence for Alzheimer's disease and MCI is described in reviews as insufficient and inconsistent. In preclinical models, aged rats with hippocampal damage showed reduced long-term memory impairment with dietary CDP-choline supplementation, and mice subjected to ischemic stroke showed SIRT1-dependent reduction in cerebral infarct volume.